CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 254 filers reported holding CRISPR THERAPEUTICS AG in Q4 2019. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,369 | +70.7% | 1,330 | +111.1% | 0.00% | +100.0% |
| Q2 2023 | $35,368 | +24.1% | 630 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $28,495 | +109496.2% | 630 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $26 | -99.9% | 630 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $41,000 | +7.9% | 630 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $38,000 | -5.0% | 630 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $40,000 | -16.7% | 630 | -0.2% | 0.00% | 0.0% |
| Q4 2021 | $48,000 | -39.2% | 631 | -10.6% | 0.00% | -50.0% |
| Q3 2021 | $79,000 | -57.8% | 706 | -38.9% | 0.00% | -60.0% |
| Q2 2021 | $187,000 | +32.6% | 1,156 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $141,000 | -33.2% | 1,156 | -15.9% | 0.00% | -42.9% |
| Q4 2020 | $211,000 | +627.6% | 1,375 | +292.9% | 0.01% | +600.0% |
| Q3 2020 | $29,000 | +11.5% | 350 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $26,000 | +73.3% | 350 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $15,000 | -28.6% | 350 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $21,000 | – | 350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |